TrianglePUBLICATIONS · 24735962
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Blood
- Publication date
- 2014 May 22
- First author
- Geisler CH
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Geisler CH
- type
- Author
- name
- van T' Veer MB
- type
- Author
- name
- Jurlander J
- type
- Author
- name
- Walewski J
- type
- Author
- name
- Tjønnfjord G
- type
- Author
- name
- Itälä Remes M
- type
- Author
- name
- Kimby E
- type
- Author
- name
- Kozak T
- type
- Author
- name
- Polliack A
- type
- Author
- name
- Wu KL
- type
- Author
- name
- Wittebol S
- type
- Author
- name
- Abrahamse-Testroote MC
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Geisler CH
- type
- Author
- name
- van T' Veer MB
- type
- Author
- name
- Jurlander J
- type
- Author
- name
- Walewski J
- type
- Author
- name
- Tjønnfjord G
- type
- Author
- name
- Itälä Remes M
- type
- Author
- name
- Kimby E
- type
- Author
- name
- Kozak T
- type
- Author
- name
- Polliack A
- type
- Author
- name
- Wu KL
- type
- Author
- name
- Wittebol S
- type
- Author
- name
- Abrahamse-Testroote MC
- type
- Author
- bibliography ids
- nci-bib-7fa32c0b148d25833afce98d
- book metadata
- content sha256
- e156d8a8da9001f49268549a786d9cda27c9402b0d3b14218613b92ebd0aacfc
- document type
- citation
- dois
- 10.1182/blood-2014-01-547737
- electronic publication date
- display
- 2014 Apr 15
- precision
- day
- year
- 2014
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:24735962
- immutable id
- pubmed:24735962@e156d8a8da9001f49268549a786d9cda27c9402b0d3b14218613b92ebd0aacfc
- journal
- abbreviation
- Blood
- issn electronic
- 1528-0020
- issn print
- 0006-4971
- issue
- 21
- name
- Blood
- nlm unique id
- 7603509
- pages
- 3255-62
- volume
- 123
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 24735962
- provenance
- batch id
- 063b6c38419f18d4021f
- provider
- NCBI PubMed ESummary
- record sha256
- 8fd9d58362ec3d8ec6786ce2066e16f10133b31c8aa1d182e92c0db5c87f6ede
- response sha256
- 5abcae41e9384a85f92695ef76b244ffd933f07a58a51082c160af8743d196ad
- retrieved at
- 2026-09-09T23:47:02.607425+00:00
- publication date
- display
- 2014 May 22
- precision
- day
- year
- 2014
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Preserved source evidence · Not medical advice